Dr. Antonio Delgado-Gonzalez is a postdoctoral research fellow in the laboratory of Prof. Garry P. Nolan under the mentorship of Dr. Wendy J. Fantl at Stanford University. His research interest lies in generating a systems-level view of ovarian cancer to develop spatial biomarkers to predict response to chemotherapy, and to identify novel therapeutic targets. Dr. Delgado-Gonzalez obtained his BSc in Pharmacy in 2014, his MSc in Molecular Biology in 2015, and his PhD in Biomedicine in 2019 from the University of Granada, Spain, under the supervision of Dr. Rosario M. Sanchez-Martin and Dr. Juan J. Diaz-Mochon. His graduate studies integrated nanotechnology with chemical approaches to develop biocompatible reagents with cellular and molecular applications, such as biomarker identification and cellular barcoding. In 2021, he joined the lab of Dr. Fantl as an Alfonso Martin Escudero postdoctoral fellow to study the tumor microenvironment (TME) of tubo-ovarian high-grade serous carcinoma (HGSC). His current work applies CODetection by indEXing, a recently developed multiplex imaging platform, to gain a comprehensive understanding of the cell types and their spatial interactions (cellular neighborhoods) within the HGSC TME. With OCRA’s Mentored Investigator Grant support, Dr. Delgado-Gonzalez will determine how cellular neighborhoods within the HGSC TME compare across anatomical sites and how they change in response to carboplatin. These studies will provide new insights into HGSC tumor biology with the potential to identify new biomarkers and therapeutic targets to predict response and overcome resistance to carboplatin respectively.